Swine flu is latest biosecurity challenge
Experts on the prevention, handling and treatment of influenza-type viruses and pathogenic material are meeting in London
Preparation for Biocontainment, biosafety and biosecurity 2009 began last year and IChemE’s advance publicity referred to the ‘near certainty of an influenza-type pandemic in the future’.
“The timing is coincidental, but it’s an opportune moment for experts to come together and discuss the likelihood and impact of a flu pandemic and what needs to be done combat the threat,” says IChemE Director of Policy, Andrew Furlong.
Speakers will discuss the release of specific pathogens, including H1N1 – a new variant of which is responsible for the swine flu outbreak; rapid response biomanufacturing of vaccines and antibodies; and patient decontamination and the temporary provision of patient isolation systems.
Interest in biocontainment and biosecurity has grown steadily in the chemical engineering community. In 2007, IChemE Fellow, Keith Plumb featured across the UK media discussing the Foot and Mouth Disease outbreak at Pirbright, Surrey and the biocontainment breach that led to the release. Now Plumb is calling for a measured response in the face of intense media speculation around the threat of ‘Mexican Flu’.
"Let's keep things in perspective,” says Plumb. “This is not 1918; and with over 30 million doses of antiviral treatments, effective against H1N1 available in the UK right now we are well placed to combat any outbreak. We should also bear in mind that there are two flu-vaccine manufacturers in the UK (Novartis and Medimmune) and whilst there may be capacity issues, both companies are technically capable of producing appropriate vaccines."
Plumb continues, “There is no evidence of pandemic in Europe at this point in time but should the threat increase, the UK has a wealth of scientific and engineering expertise which can be deployed to ramp up the countermeasures necessary to protect the population at large. Ultimately, the problem won't be solved by government or some sort of national security clampdown - it's the medical profession supported by engineers and scientists who will see us through,” adds Plumb.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.